|
1
|
Baumgart DC and Carding SR: Inflammatory
bowel disease: cause and immunobiology. Lancet. 369:1627–1640.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bouma G and Strober W: The immunological
and genetic basis of inflammatory bowel disease. Nat Rev Immunol.
3:521–533. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xavier RJ and Podolsky DK: Unravelling the
pathogenesis of inflammatory bowel disease. Nature. 448:427–434.
2007. View Article : Google Scholar
|
|
4
|
Baumgart DC and Sandborn WJ: Inflammatory
bowel disease: clinical aspects and established and evolving
therapies. Lancet. 369:1641–1657. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Himmel ME, Hardenberg G, Piccirillo CA, et
al: The role of T-regulatory cells and Toll-like receptors in the
pathogenesis of human inflammatory bowel disease. Immunology.
125:145–153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fiocchi C: Towards a ‘cure’ for IBD. Dig
Dis. 30:428–433. 2012.
|
|
7
|
Shevach EM: Mechanisms of
foxp3+ T regulatory cell-mediated suppression. Immunity.
30:636–645. 2009.
|
|
8
|
Wing K and Sakaguchi S: Regulatory T cells
exert checks and balances on self tolerance and autoimmunity. Nat
Immunol. 11:7–13. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bacchetta R, Passerini L, Gambineri E, et
al: Defective regulatory and effector T cell functions in patients
with FOXP3 mutations. J Clin Invest. 116:1713–1722. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McMurchy AN, Di Nunzio S, Roncarolo MG, et
al: Molecular regulation of cellular immunity by FOXP3. Adv Exp Med
Biol. 665:30–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fontenot JD, Gavin MA and Rudensky AY:
Foxp3 programs the development and function of
CD4+CD25+ regulatory T cells. Nat Immunol.
4:330–336. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mottet C, Uhlig HH and Powrie F: Cutting
edge: cure of colitis by CD4+CD25+ regulatory
T cells. J Immunol. 170:3939–3943. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yi T and Song SU: Immunomodulatory
properties of mesenchymal stem cells and their therapeutic
applications. Arch Pharm Res. 35:213–221. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Potian JA, Aviv H, Ponzio NM, et al:
Veto-like activity of mesenchymal stem cells: functional
discrimination between cellular responses to alloantigens and
recall antigens. J Immunol. 171:3426–3434. 2003. View Article : Google Scholar
|
|
15
|
Le Blanc K, Tammik C, Rosendahl K, et al:
HLA expression and immunologic properties of differentiated and
undifferentiated mesenchymal stem cells. Exp Hematol. 31:890–896.
2003.PubMed/NCBI
|
|
16
|
Engela AU, Baan CC, Dor FJ, et al: On the
interactions between mesenchymal stem cells and regulatory T cells
for immunomodulation in transplantation. Front Immunol. 3:1262012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Le Blanc K, Frassoni F, Ball L, et al:
Mesenchymal stem cells for treatment of steroid-resistant, severe,
acute graft-versus-host disease: a phase II study. Lancet.
371:1579–1586. 2008.
|
|
18
|
Dalal J, Gandy K and Domen J: Role of
mesenchymal stem cell therapy in Crohn’s disease. Pediatr Res.
71:445–451. 2012.
|
|
19
|
Sun S, Guo Z, Xiao X, et al: Isolation of
mouse marrow mesenchymal progenitors by a novel and reliable
method. Stem Cells. 21:527–535. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morris GP, Beck PL, Herridge MS, et al:
Hapten-induced model of chronic inflammation and ulceration in the
rat colon. Gastroenterology. 96:795–803. 1989.PubMed/NCBI
|
|
21
|
Vowinkel T, Kalogeris TJ, Mori M, et al:
Impact of dextran sulfate sodium load on the severity of
inflammation in experimental colitis. Dig Dis Sci. 49:556–564.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
González R, Rodríguez S, Romay C, et al:
Anti-inflammatory activity of phycocyanin extract in acetic
acid-induced colitis in rats. Parmacol Res. 39:55–59. 1999.
|
|
23
|
Powrie F, Correaoliveira R, Mauze S, et
al: Regulatory interactions between Cd45Rb(high) and Cd45Rb(low)
Cd4(+) T-cells are important for the balance between protective and
pathogenic cell-mediated immunity. J Exp Med. 179:589–600.
1994.
|
|
24
|
Read S, Malmstrom V and Powrie F:
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role
in the function of CD25(+)CD4(+) regulatory cells that control
intestinal inflammation. J Exp Med. 192:295–302. 2000.
|
|
25
|
Strober W: Animal models of inflammatory
bowel disease - an overview. Dig Dis Sci. 30:3S–10S. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Neuman MG: Signaling for inflammation and
repair in inflammatory bowel disease. Rom J Gastroenterol.
13:309–316. 2004.PubMed/NCBI
|
|
27
|
Reiff C and Kelly D: Inflammatory bowel
disease, gut bacteria and probiotic therapy. Int J Med Microbiol.
300:25–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cho JH: The genetics and
immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol.
8:458–466. 2008. View
Article : Google Scholar
|
|
29
|
Chaperon EA, Selner JC and Claman HN:
Migration of antibody-forming cells and antigen-sensitive
precursors between spleen, thymus and bone marrow. Immunology.
14:553–561. 1968.PubMed/NCBI
|
|
30
|
Sakaguchi S, Sakaguchi N, Asano M, et al:
Immunologic self-tolerance maintained by activated T cells
expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single
mechanism of self-tolerance causes various autoimmune diseases. J
Immunol. 155:1151–1164. 1995.
|
|
31
|
Takahashi T, Kuniyasu Y, Toda M, Sakaguchi
N, Itoh M, Iwata M, et al: Immunologic self-tolerance maintained by
CD25+CD4+ naturally anergic and suppressive T
cells: induction of autoimmune disease by breaking their
anergic/suppressive state. Int Immunol. 10:1969–1980. 1998.
|
|
32
|
d’Hennezel E, Bin Dhuban K, Torgerson T,
et al: The immunogenetics of immune dysregulation,
polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med
Genet. 49:291–302. 2012.PubMed/NCBI
|
|
33
|
Maloy KJ: Induction and regulation of
inflammatory bowel disease in immunodeficient mice by distinct
CD4+ T-cell subsets. Methods Mol Biol. 380:327–335.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eri R, McGuckin MA and Wadley R: T cell
transfer model of colitis: a great tool to assess the contribution
of T cells in chronic intestinal inflammation. Methods Mol Biol.
844:261–275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tolar J, Le Blanc K, Keating A and Blazar
BR: Concise review: hitting the right spot with mesenchymal stromal
cells. Stem Cells. 28:1446–1455. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Casiraghi F, Azzollini N, Cassis P, et al:
Pretransplant infusion of mesenchymal stem cells prolongs the
survival of a semiallogeneic heart transplant through the
generation of regulatory T cells. J Immunol. 181:3933–3946. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ge W, Jiang J, Arp J, et al: Regulatory
T-cell generation and kidney allograft tolerance induced by
mesenchymal stem cells associated with indoleamine 2,3-dioxygenase
expression. Transplantation. 90:1312–1320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li Z, Arijs I, De Hertogh G, et al:
Reciprocal changes of Foxp3 expression in blood and intestinal
mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis.
16:1299–1310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Djouad F, Plence P, Bony C, et al:
Immunosuppressive effect of mesenchymal stem cells favors tumor
growth in allogeneic animals. Blood. 102:3837–3844. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Karp JM and Leng Teo GS: Mesenchymal stem
cell homing: the devil is in the details. Cell Stem Cell.
4:206–216. 2009. View Article : Google Scholar : PubMed/NCBI
|
